OptiBiotix Health PLC Launch of GoFigure range with Apollo Hospitals (8392Z)
20 Septembre 2022 - 8:00AM
UK Regulatory
TIDMOPTI
RNS Number : 8392Z
OptiBiotix Health PLC
20 September 2022
OptiBiotix Health plc
("OptiBiotix" or the "Company" or the "Group")
Launch of GoFigure range with Apollo Hospitals & Pharmacies
in India
OptiBiotix Ltd, a wholly owned subsidiary of OptiBiotix Health
plc (AIM: OPTI) and a life sciences business developing patented
science and human study-based compounds that modulate the
microbiome to address a range of health related issues such as
metabolic syndrome and diabetes, systemic low-grade inflammation,
obesity, cardiovascular disease, high cholesterol and healthy aging
announces, further to the exclusive sales agreement announced 9
December 2021, that its GoFigure range was officially launched by
Apollo Hospitals & Pharmacies on 18 September 2022.
Apollo Pharmacies ( https://www.apollopharmacy.in/ ), owned by
Apollo Hospitals through Apollo Healthco, is the largest and most
trusted branded pharmacy networks, with 5,000 pharmacy outlets
throughout India.
GoFigure is OptiBiotix's direct-to-consumer (D2C) (
https://gofigurediet.com/ ) range of weight management products
which combines various meal replacement, healthy snacking options
and powdered beverages containing its multi award winning weight
management ingredient SlimBiome (R) . The GoFigure portfolio is
available for retailers and pharmacies worldwide.
SlimBiome (R) is OptiBiotix's proprietary weight management aid.
It supports people on a calorie restricted diet to lose weight
faster. Human studies show that it reduces hunger, makes you feel
full for longer, reduces food cravings and uniquely changes the
microbiome over time in the direction of a lean person's
microbiome. SlimBiome (R) carries a wealth of health claims and is
available to formulators worldwide.
Apollo's GoFigure product launch consists of meal replacement
shakes and powdered beverage shots and will be expanded over time
with extra flavours and new product forms such as bars. OptiBiotix
is responsible for product development and manufacturing locally in
India and has tailored the range jointly with the Apollo team to
suit the unique needs of Indian consumers.
The launch has taken place both in store as well as on the newly
created Apollo 24|7 online customer platform. Initially the product
will be available in 120 top stores in major cities across India
and then expanded from there.
René Kamminga, C EO of O pti B i oti x Limited, c o mmented :
"We are very pleased that our GoFigure products are now available
to the consumer in India through Apollo Pharmacies, a leading
pharmacy chain in India. Our GoFigure range of weight management
products have been specifically formulated to support consumers on
a weight loss journey by reducing hunger and food cravings as well
as modifying the gut microbiome in the direction of a lean person.
18 September marks both the 40(th) anniversary of the group and the
5000(th) pharmacy opening for Apollo so it is significant to launch
on this memorable day. This launch is another important step in
building sales and brand presence for OptiBiotix's solutions with
major partners around the world."
This announcement contains inside information for the purposes
of UK Market Abuse Regulation and the Directors of the Company are
responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook below
OptiBiotix Health Ltd
Rene Kamminga
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
Cenkos Securities plc (Broker) Tel: 020 7397 8900
Callum Davidson / Neil McDonald
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
Caution regarding forward looking statements
Certain statements in this announcement, are, or may be deemed
to be, forward looking statements. Forward looking statements are
identi ed by their use of terms and phrases such as "believe",
"could", "should" "envisage", "estimate", "intend", "may", "plan",
"potentially", "expect", "will" or the negative of those,
variations or comparable expressions, including references to
assumptions. These forward looking statements are not based on
historical facts but rather on the Directors' current expectations
and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures
(including the amount, nature and sources of funding thereof),
competitive advantages, business prospects and opportunities. Such
forward looking statements re ect the Directors' current beliefs
and assumptions and are based on information currently available to
the Directors.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFLFFLAEIDLIF
(END) Dow Jones Newswires
September 20, 2022 02:00 ET (06:00 GMT)
OptiBiotix Health (AQSE:OPTI.GB)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
OptiBiotix Health (AQSE:OPTI.GB)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024